Differential task-related fMRI effects of a single dose of guanfacine and lisdexamfetamine in youth with ADHD: a randomised, double-blind, placebo-controlled crossover study
This randomized, double-blind, crossover study demonstrates that a single dose of lisdexamfetamine produces stronger and more extensive normalization of fronto-striato-thalamic and posterior brain activation, along with improved task performance, compared to guanfacine in youth with ADHD during executive function tasks.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
The human brain is a vast, interconnected network that must constantly decide what to focus on and what to ignore. For most people, this process happens automatically, but for those with attention-deficit/hyperactivity disorder, or ADHD, the brain's internal filters often struggle to keep up. This condition is characterized by persistent difficulties with attention, hyperactivity, and impulsivity, affecting millions of children and adolescents worldwide. Scientists have long known that certain medications can help manage these symptoms, but the question of exactly how these drugs change the brain's activity has remained somewhat of a mystery. While some treatments are well-established, newer medications have been introduced with less clarity regarding their specific effects on brain function. Understanding whether these different drugs work in the same way or through distinct pathways is crucial, as it could help doctors choose the right treatment for the right child, moving beyond a trial-and-error approach to a more precise understanding of how these medicines restore balance to the brain's attention systems.
In a recent study, researchers set out to compare two different types of medication used to treat ADHD in young people: lisdexamfetamine, a stimulant, and guanfacine, a non-stimulant. The team wanted to see how a single dose of each drug changed brain activity while the participants performed tasks that required focus, memory, and the ability to stop an action. They recruited a group of teenagers and young adults with ADHD and scanned their brains using functional magnetic resonance imaging, a technology that measures blood flow to see which parts of the brain are working hard at a given moment. The participants underwent three separate scanning sessions, each separated by a week to ensure the previous medication had left their system. In a random order, they received either the stimulant, the non-stimulant, or a placebo, which is an inactive substance that looks like the real medicine. To provide a baseline for comparison, the researchers also scanned a group of young people without ADHD who did not take any medication.
The results revealed that the two drugs did not work in the same way. When the participants took the stimulant, lisdexamfetamine, their brains showed increased activity in specific areas responsible for controlling movement and attention, particularly in deep structures known as the basal ganglia. This drug also boosted activity in the back parts of the brain involved in visual processing and spatial awareness. In contrast, the non-stimulant, guanfacine, did not produce these same increases in the basal ganglia or the visual areas. Instead, both drugs shared a common effect: they increased activity in a region on the left side of the brain associated with processing language and sound, which likely helped the participants hold information in their working memory. However, the stimulant appeared to have a stronger and more unique influence on the brain's ability to focus and inhibit impulses.
The study also looked at how the medications affected the participants' performance on the tasks. The young people with ADHD who took the placebo were slower and less accurate at stopping their responses compared to the healthy control group. After taking the stimulant, their performance improved significantly, bringing their reaction times close to those of the healthy controls. This suggests that the stimulant helped normalize their ability to control their impulses. The non-stimulant, however, did not lead to the same level of improvement in stopping speed. While the non-stimulant did help with some aspects of brain activity, it did not seem to correct the specific underactivity in the visual and attention centers that the stimulant did. In fact, in some areas related to attention, the non-stimulant group showed even less activity than the healthy controls, hinting that this drug might affect the brain's alertness levels differently.
These findings offer a clearer picture of how different medications interact with the ADHD brain. The study suggests that while both drugs can be helpful, they engage different neural circuits. The stimulant lisdexamfetamine appears to be more effective at waking up the brain's deep control centers and visual attention networks, leading to better performance on tasks requiring impulse control. The non-stimulant guanfacine works through a different path, sharing some benefits but lacking the same powerful effect on the brain's visual and motor control regions. This distinction is important because it implies that not all ADHD medications are interchangeable; what works for one person's brain chemistry might not work for another's. The researchers noted that their study was relatively small and that the non-stimulant might take longer to show its full effects, so these results should be seen as a promising first step rather than a final answer. Nevertheless, the work provides a tangible map of how these drugs change the brain, offering hope for more personalized and effective treatments in the future.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.